Squamous lung carcinoma data add further weight to promise of Oncolytics' Reolysin
This article was originally published in Scrip
Executive Summary
The day after Oncolytics Biotech said it would split the first Phase III clinical trial for Reolysin - the Canadian company's proprietary formulation of human reovirus - into two separate patient groups, it announced positive interim results from a Phase II trial in squamous cell carcinoma of the lung (SCCLC) that justified continuation of the 55-patient study.